Australia's main stock market index, the ASX200, fell to 8580 points on July 11, 2025, losing 0.11% from the previous session. Over the past month, the index has climbed 0.18% and is up 7.80% compared to the same time last year, according to trading on a contract for difference (CFD) that tracks this benchmark index from Australia. Australia Stock Market Index - values, historical data, forecasts and news - updated on July of 2025.

The S&P/ASX 200 index, the most prominent index of stocks listed on the Australian Securities Exchange (ASX), lost over one fifth of its value between the end of February and the end of March 2020, owing to the economic impact of the global coronavirus (COVID-19) pandemic. It has since recovered, and surpassed its pre-corona level in April 2021. Despite fluctuations, it reached its highest value in January 2025 at 8532.3 during this period.The S&P/ASX 200 index is considered the benchmark index for the Australian share market and contains the 200 largest companies listed on the ASX.

Australia's main stock market index, the ASX200, fell to 8541 points on July 14, 2025, losing 0.46% from the previous session. Over the past month, the index has declined 0.09%, though it remains 6.52% higher than a year ago, according to trading on a contract for difference (CFD) that tracks this benchmark index from Australia. Australia Stock Market Index - values, historical data, forecasts and news - updated on July of 2025.

Key information about Australia S&P/ASX 200

• Australia S&P/ASX 200 closed at 8,172.4 points in Feb 2025, compared with 8,532.3 points at the previous month end
• Australia Equity Market Index: Month End: ASX: S&P/ASX 200 data is updated monthly, available from May 1992 to Feb 2025, with an average number of 4,604.3 points
• The data reached an all-time high of 8,532.3 points in Jan 2025 and a record low of 1,428.8 points in Oct 1992

The S&P/ASX 200 Index (XJO) is recognised as the investable benchmark for the Australian equity market, it addresses the needs of investment managers to benchmark against a portfolio characterised by sufficient size and liquidity. The S&P/ASX 200 is comprised of the S&P/ASX 100 plus an additional 100 stocks. It forms the basis for the S&P/ASX 200 Index Future and Options and the SPDR S&P/ASX 200 Exchange Traded Fund (ETF)

BackgroundDoxorubicin (DOX), a widely employed chemotherapeutic agent in cancer treatment, has seen restricted use in recent years owing to its associated cardiotoxicity. Current reports indicate that doxorubicin-induced cardiotoxicity (DIC) is a complex phenomenon involving various modes of cell death. Astaxanthin (ASX), a natural carotenoid pigment, has garnered significant attention for its numerous health benefits. Recent studies have shown that ASX has a broad and effective cardiovascular protective effect. Our study aims to investigate the protective effects of ASX against DIC and elucidate its underlying mechanisms. This has substantial practical significance for the clinical application of DOX.MethodsBioinformatic analyses were conducted using transcriptomic data from the gene expression omnibus (GEO) database to identify key mechanisms underlying DIC. Network pharmacology was employed to predict the potential pathways and targets through which ASX exerts its effects on DIC. In vitro experiments, following pretreatment with ASX, H9C2 cells were exposed to DOX. Cell viability, injury and the protein expression levels associated with ferroptosis and autophagy were assessed. In the animal experiments, rats underwent 4 weeks of gavage treatment with various doses of ASX, followed by intraperitoneal injections of DOX every 2 days during the final week. Histological, serum, and protein analyses were conducted to evaluate the effects of ASX on DIC.ResultsThe bioinformatics analysis revealed that ferroptosis and autophagy are closely associated with the development of DIC. ASX may exert an anti-DIC effect by modulating ferroptosis and autophagy. The experimental results show that ASX significantly mitigates DOX-induced myocardial tissue damage, inflammatory response, oxidative stress, and damage to H9C2 cells. Mechanistically, ASX markedly ameliorates levels of ferroptosis and autophagy both in vitro and in vivo. Specifically, ASX upregulates solute carrier family 7 member 11 (SLC7A11) and glutathione peroxidase 4 (GPX4), while downregulating the expression of transferrin receptor 1 (TFRC), ferritin heavy chain (FTH1) and ferritin light chain (FTL). Additionally, ASX enhances the expression of P62 and decreases levels of Beclin1 and microtubule-associated proteins light chain 3 (LC3).ConclusionOur results indicate that ferroptosis and autophagy are critical factors influencing the occurrence and progression of DOX-induced cardiotoxicity. ASX can alleviate DIC by inhibiting ferroptosis and autophagy.

Iron Ore fell to 96.71 USD/T on July 11, 2025, down 0.05% from the previous day. Over the past month, Iron Ore's price has risen 1.31%, but it is still 11.74% lower than a year ago, according to trading on a contract for difference (CFD) that tracks the benchmark market for this commodity. Iron Ore - values, historical data, forecasts and news - updated on July of 2025.

The yield on Australia 10Y Bond Yield rose to 4.38% on July 14, 2025, marking a 0.05 percentage point increase from the previous session. Over the past month, the yield has edged up by 0.13 points and is 0.04 points higher than a year ago, according to over-the-counter interbank yield quotes for this government bond maturity. Australia 10-Year Government Bond Yield - values, historical data, forecasts and news - updated on July of 2025.

Bank Bill Swap Rate in Australia remained unchanged at 3.58 percent on Tuesday July 8. This dataset includes a chart with historical data for Australia Bank Bill Swap Rate.